Titan Pharmaceuticals, Inc. (TTNP)

7.01 -0.20 (-2.77%) As of 09:32AM EDT. Market open.

Titan Pharmaceuticals, Inc.

400 Oyster Point Boulevard
Suite 505
South San Francisco, CA 94080
United States
650 244 4990
https://www.titanpharm.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 4

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. David Elliot Lazar	CEO & Principal Financial Officer	1.42M	N/A	1991
Dr. Katherine L. Beebe-DeVarney Ph.D.	President, COO & Director	462k	N/A	1961
Mr. Mike Fritz	National Sales Director	N/A	N/A	N/A
Jennifer Kiernan	Executive Assistant to CEO & Investor Communications Coordinator	N/A	N/A	N/A
Joe Schrei	Executive Director of Commercial Operations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

Corporate Governance

Titan Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.